The company’s U.S.-listed shares fell over 13% in premarket trading and dragged down other stocks in the industry between 2% and 5%. Medical cannabis was the only bright spot, while Canopy’s revenue from recreational markets at home in Canada and internationally slumped in double-digit percentages. Ontario-based Canopy Growth’s net loss attributable to the company widened to C$1.30 billion ($946.21 million), or C$3.72 per share, in the quarter ended March 31, from C$379.5 million, or C$1.10 per share, a year ago. …read more
Source:: Yahoo Finance
